Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Asset Writedowns and Impairment for 18 consecutive years, with $113.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Asset Writedowns and Impairment rose 14.14% year-over-year to $113.0 million; the trailing twelve-month figure through Jun 2026 stood at $975.0 million (up 51.87% YoY), and the FY2025 full-year result was $1.0 billion, down 19.37% from the prior year.
• Asset Writedowns and Impairment improved to $113.0 million in Q2 2026 per TEVA's latest filing, from $10.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $810.0 million in Q2 2022 and bottomed at -$600.0 million in Q4 2022.
• Historically, Asset Writedowns and Impairment has averaged $178.2 million across 5 years, with a median of $89.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Asset Writedowns and Impairment sank 427.87% in 2022, then soared 660.29% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at -$600.0 million in 2022, then surged by 111.33% to $68.0 million in 2023, then jumped by 660.29% to $517.0 million in 2024, then jumped by 49.52% to $773.0 million in 2025, then plunged by 85.38% to $113.0 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $113.0 million, $10.0 million, and $773.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.